Metal complexes of bleomycin: Evaluation of [Rh-105]-bleomycin for use in targeted radiotherapy

Nuclear Medicine and Biology

Volumn 26, Issue 4, 1999, Pages 421-430

  Brooks, R C ^a,c   Carnochan, P ^a   Vollano, J F ^c   Powell, N A ^b   Zweit, J ^a   Sosabowski, J K ^a   Martellucci, S ^c   Darkes, M C ^c   Fricker, S P ^b   Murrer, B A ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JOHNSON MATTHEY TECHNOLOGY CENTRE   (United Kingdom)

^c Johnson Matthey   (United States)

Author keywords

Biodistribution; Bleomycin; Pharmacokinetics; Rhodium 105; Targeted radiotherapy

Indexed keywords

BLEOMYCIN CO 57; BLEOMYCIN COBALT; BLEOMYCIN RHODIUM COMPLEX; BLEOMYCIN SULFATE; COBALT 57; METAL COMPLEX; RHODIUM; RHODIUM 105; RHODIUM COMPLEX; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; DAUDI CELL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG STABILITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; NONHUMAN; RADIOISOTOPE DISTRIBUTION; RAT; SOLID TUMOR;

ANIMALS; BLEOMYCIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; MALE; NEOPLASMS, EXPERIMENTAL; RADIOISOTOPES; RATS; RHODIUM; TISSUE DISTRIBUTION;

EID: 0032982674     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(98)00109-7     Document Type: Article

References (30)

1. Chang C.-H., Mears C.F. Cobalt bleomycin and deoxynucleic acid Sequence-dependent interaction, action spectrum for nicking, and indifference to oxygen . Biochemistry. 23:1984;2268-2274.
2. Clarke M. J. (1980) Oncological implications of the chemistry of ruthenium. In: Metal Ions in Biological Systems, Sigel H., Ed. Vol. 11, 231-283. Marcel Dekker, New York.
3. Clarke M.D., Galang R.D., Rodriguez V.M., Kumar R., Pell S., Bryan D.M. Chemical consideration in the design of ruthenium anticancer agents. Nicolini M. Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy. 1988;582-600 Nijhoff, Boston.
4. Dabrowiak J.C. The coordination chemistry of bleomycin A review . J. Inorg. Biochem. 13:1980;317-337.
5. D'Andere A.D., Haseltine W.A. Sequence specific cleavage of DNA by the antitumour antibiotics neocarzinostatin and bleomycin. Proc. Natl. Acad. Sci. USA. 75:1978;3608-3612.
6. DeRiemer L.H., Meares C.F., Goodwin D.A., Diamanti C.I. BLEDTA II Synthesis of a new tumour-visualising derivative of Co(III)-bleomycin . J. Labelled Compd. Radiopharm. 18:1980;1517-1533.
7. Eckelman W.C., Kubota H., Siegel B.A., Komai T., Rzeszotarski W.J., Reba R.C. Iodinated bleomycin An unsatisfactory radiopharmaceutical for tumour localisation . J. Nucl. Med. 17:1976;385-388.
8. Fiedler H.-P., Wachter J. High-performance liquid chromatographic determination of bleomycins. J. Chromatogr. 536:1991;343-347.
9. 105Rh as a potential radiotherapeutic agent. Int. J. Appl. Radiat. Isotopes. 39:1988;257-260.
10. Grove R.B., Eckelman W.C., Reba R.C. Distribution of labelled bleomycin in normal and tumour-bearing mice. J. Nucl. Med. 14:1974;917-919.
11. Hirschberg H., Thorsby E. Specific in vitro elimination of histocompatibility antigen reactive cells. J. Immunol. Methods. 3:1973;151.
12. 57Co-bleomycin scanning in the evaluation of tumours. Am. J. Roentgenol. 129:1977;267-273.
13. Kairemo K.J.A., Ramsay H.A., Tagesson M., Jekunen A.P., Paavonen T.K., Jääskelä-Saari H.A., Liewendahl K., Ljunggren K., Savolainen S., Strand S.-E. Indium-111 bleomycin complex for radiochemotherapy of head and neck cancer - Dosimetric and biokinetic aspects. Eur. J. Nucl. Med. 23:1996;631-638.
14. Kobayashi H., Yoo T.M., Kim I.S., Kim M.K., Le N., Webber K.O., Pastan I., Paik C.H., Eckelman W.C., Carrasquillo L. L-Lysine effectively blocks renal uptake of I-125-labelled or Tc-99m-labelled anti-tac disulfide-stabilized fv fragment. Cancer Res. 56:1996;3788-3795.
15. Kono A., Matsushima Y., Kojima M., Maeda T. Cobalt chelate of bleomycin I. Physicochemical properties and distribution in tumour-bearing mice. Chem. Pharm. Bull. 25:1977;1725-1731.
16. Kuwahara J., Sugira Y. Sequence specific recognition and cleavage of DNA by metallobleomycin. Minor groove binding and possible interaction mode. Proc. Natl. Acad. Sci. USA. 85:1988;2459-2463.
17. 57Co. Intérêt dans la diagnostic der tumeurs malignes et de leur extension. Nov. Presse Med. 1:1972;85-98.
18. 105Rhodium using a new pentadentate bifunctional ligand. Bioconjugate Chem. 1:1990;191-197.
19. Rund J.V., Basolo F., Pearson R.G. Catalysis of substitution reactions of rhodium(III) complexes. The reaction of aquopentachlororhodate(III) ion with pyridine. Inorg. Chem. 3:1963;658-661.
20. 64Cu-bleomycin. J. Nucl. Med. 16:1975;127-131.
21. Stern P.H., Halpern S.E., Hagan P.L., Howell S.B., Dabbs J.E., Gordon R.M. Cytotoxic activity, tumour accumulation and tissue distribution of Ruthenium-103-labelled bleomycin. J. Natl. Cancer Inst. 66:1981;807-811.
22. Sugiura Y. Oxygen binding to cobalt(II)-bleomycin. J. Antibiot. 31:1978;1206-1208.
23. Suzuki H., Nagai K., Yamaki H., Tanaka N., Umezawa H. On the mechanism of action of bleomycin: Scission of DNA strands in vitro and in vivo. J. Antibiot. (Toyko). 22:1969;446-448.
24. Thakur M.L. The preparation of Indium-111 labelled bleomycin for tumour localisation. Int. J. Appl. Radiat. Isotopes. 24:1973;357-369.
25. Umezawa H., Suhara Y., Takita T., Maeda K. Purification of bleomycins. J. Antibiot. 19:1966;210-215.
26. 105Rhodium tetrathiamacrocycle (S4) with potential for formulating bifunctional chelates (BFCs). J. Nucl. Med. 35:1994;41P.
27. 131I labelled B72.3 MOAB. J. Nucl. Med. 35:1994;241P.
28. 2 complex. J. Inorg. Biochem. 12:1980;45-55.
29. Young H., Carnochan P., Zweit J., Babich J., Cherry S. and Ott R. (1994 ) Evaluation of copper(II)-pyruvaldehyde bis (N-4-methylthiosemicarbazone) for tissue blood flow measurement using a trapped tracer model. Eur. J. Nucl. Med. 21, 336-341.
30. 57Co-bleomycin. Int. J. Nucl. Med. Biol. 4:1977;216-218.